Padayatty and colleagues report on 3 well-documented cases of advanced cancers, confirmed by histopathologic review, where patients had unexpectedly long survival times after receiving high-dose intravenous vitamin C therapy. They assessed the clinical details of each case in accordance with National Cancer Institute (NCI) Best Case Series guidelines, and found that the case reports indicate that the role of high-dose intravenous vitamin C therapy in cancer treatment should be reassessed.
p. 937 Intravenously administered vitamin C as cancer therapy: three cases
-- S.J. Padayatty et al
http://www.cmaj.ca/pressrelease/pg937.pdf
Canadian Medical Association Journal